Abstract
Ticagrelor is an orally active, reversibly bind of the P2Y12 receptor that can prevent ADP-mediated platelet activation and has a faster onset of action than clopidogrel. A stability-indicating HPLC method for the determination of ticagrelor in coated tablets was developed and validated. Chromatographic analysis was performed in a Shimadzu liquid chromatograph, equipped with Phemomenex® C18 column (250 x 4.6 mm, 5 μm), using a mobile phase composed of acetonitrile: water with 0.5% triethylamine (57:43 v/v) pH 7.0, at 0.7 ml/min flow rate and injection volume of 20 μl. Under the conditions established, the method demonstrated to be specific, without interference from formulation excipients, stability- indicating, linear (r = 0.9990) in the concentration range of 45.0 to 105.0 μg/ml, precise (RSD=0.71), accurate (99.61% of mean recovery) and robust. It can be successfully applied to ticagrelor tablets quality control, being adequate for routine analysis.
Keywords: Antiplatelet, HPLC, quality control, stability-indicating assay, tablets, ticagrelor.
Current Pharmaceutical Analysis
Title:Determination of the New Antiplatelet Agent Ticagrelor in Tablets by Stability-Indicating HPLC Method
Volume: 10 Issue: 4
Author(s): Caren Gobetti, Rubia Lazzaretti Pereira, Andreas Sebastian Loureiro Mendez and Cássia Virginia Garcia
Affiliation:
Keywords: Antiplatelet, HPLC, quality control, stability-indicating assay, tablets, ticagrelor.
Abstract: Ticagrelor is an orally active, reversibly bind of the P2Y12 receptor that can prevent ADP-mediated platelet activation and has a faster onset of action than clopidogrel. A stability-indicating HPLC method for the determination of ticagrelor in coated tablets was developed and validated. Chromatographic analysis was performed in a Shimadzu liquid chromatograph, equipped with Phemomenex® C18 column (250 x 4.6 mm, 5 μm), using a mobile phase composed of acetonitrile: water with 0.5% triethylamine (57:43 v/v) pH 7.0, at 0.7 ml/min flow rate and injection volume of 20 μl. Under the conditions established, the method demonstrated to be specific, without interference from formulation excipients, stability- indicating, linear (r = 0.9990) in the concentration range of 45.0 to 105.0 μg/ml, precise (RSD=0.71), accurate (99.61% of mean recovery) and robust. It can be successfully applied to ticagrelor tablets quality control, being adequate for routine analysis.
Export Options
About this article
Cite this article as:
Gobetti Caren, Pereira Lazzaretti Rubia, Mendez Sebastian Loureiro Andreas and Garcia Virginia Cássia, Determination of the New Antiplatelet Agent Ticagrelor in Tablets by Stability-Indicating HPLC Method, Current Pharmaceutical Analysis 2014; 10 (4) . https://dx.doi.org/10.2174/1573412910666140610211656
DOI https://dx.doi.org/10.2174/1573412910666140610211656 |
Print ISSN 1573-4129 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-676X |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Scutellarin Mediates Cytochrome P450 3A4 and 2C19 Expression via
Pregnane X Receptor and Constitutive Androstane Receptor
Current Molecular Pharmacology Near-Infrared Spectroscopy (NIRS): A Non-Invasive In Vivo Methodology for Analysis of Brain Vascular and Metabolic Activities in Real Time in Rodents
Current Vascular Pharmacology Deep Inspiration Breath-hold (DIBH) Technique to Reduce Cardiac Radiation Dose in the Management of Breast Cancer
Current Cancer Therapy Reviews Effect of Non-Statin Lipid Lowering and Anti-Obesity Drugs on LDL Subfractions in Patients with Mixed Dyslipidaemia
Current Vascular Pharmacology Advancing Drug Therapy for Brain Tumours: A Current Review of the Pro-inflammatory Peptide Substance P and its Antagonists as Anti-cancer Agents
Recent Patents on CNS Drug Discovery (Discontinued) Obesity and Coronary Microvascular Disease – Implications for Adipose Tissue-Mediated Remote Inflammatory Response
Current Vascular Pharmacology Evidence for a Putative Relationship Between Type 2 Diabetes and Neoplasia with Particular Reference to Breast Cancer: Role of Hormones, Growth Factors and Specific Receptors
Current Drug Targets - Immune, Endocrine & Metabolic Disorders Therapeutic Use of Calcitriol
Current Vascular Pharmacology The New Adipose Tissue and Adipocytokines
Current Diabetes Reviews Numerical Studies of Blood Flow in Left Coronary Model
Recent Advances in Computer Science and Communications The Potential of Embryonic Stem Cells Combined with -omics Technologies as Model Systems for Toxicology
Current Medicinal Chemistry Chromatographic Retention Parameters in Medicinal Chemistry and Molecular Pharmacology
Current Medicinal Chemistry The Role of αA-Crystallin in Experimental Autoimmune Uveitis
Current Molecular Medicine Natural Agents Modulating ACE-2: A Review of Compounds with Potential against SARS-CoV-2 Infections
Current Pharmaceutical Design Total Knee Replacement and Chemical Thromboprophylaxis: Current Evidence
Current Vascular Pharmacology Meet Our Editorial Board Member:
Current Drug Safety Patent Selections
Recent Patents on Nanotechnology Can a Direct IADL Measure Detect Deficits in Persons with MCI?
Current Alzheimer Research Aldosterone and Mineralocorticoid Receptor Antagonists on Pulmonary Hypertension and Right Ventricular Failure: A Review
Current Pharmaceutical Design Update on Alzheimer’s Disease Therapeutics
Reviews on Recent Clinical Trials